Xcout IntelFerrosa Therapeutics
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Subscribe to see Ferrosa Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ferrosa Therapeutics at a glance
Ferrosa Therapeutics is a biotechnology company headquartered in Switzerland. Its most recent funding round, Seed, raised $3.5M in April 2026. Xcout tracks 3 named people at Ferrosa Therapeutics, including Martin Stern (CEO & Co-Founder · Board Member).
Ferrosa Therapeutics leadership
- Martin SternCEO & Co-Founder · Board Member
- Sara Núñez-GarcíaBoard Member & Co-Founder
- Sascha Oliver BucherBoard Member & Co-Founder
Ferrosa Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $3.5M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Ferrosa Therapeutics competitors
A few of Ferrosa Therapeutics's closest competitors — see the full list of competitors and alternatives →
Sidero Bioscience is a clinical-stage biotechnology company that develops natural iron supplement products to address iron deficiency and nutritional health. Its proprietary SideroSorb platform and BioFe iron complex utilize a unique uptake mechanism designed to improve absorption and minimize gastrointestinal side effects compared to traditional iron therapies.
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Amporin Pharmaceuticals AG is a Swiss biotechnology company founded in Basel in 2024. The firm focuses on developing a new class of small-molecule drugs designed to target toxic membrane mechanisms.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Mosanna Therapeutics is a biopharmaceutical company with offices in Redwood City, California and Basel, Switzerland. The company focuses on developing novel treatments for metabolic and cardiovascular diseases. It launched with $80 million in funding to advance its clinical pipeline.
Get Ferrosa Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ferrosa Therapeutics in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access